<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03178032</url>
  </required_header>
  <id_info>
    <org_study_id>D24-DIPG</org_study_id>
    <nct_id>NCT03178032</nct_id>
  </id_info>
  <brief_title>Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas</brief_title>
  <official_title>Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DNAtrix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alcyone Lifesciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oncolytic adenovirus for pediatric naive DIPG, to be infused after tumor biopsy through the
      same trajectory in the cerebellar peduncle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diffuse pontine gliomas (DIPG) are one of the most lethal pediatric tumors. All treatment
      approaches for these tumors have failed, leaving a terrible prospect with median survival
      under one year, and survival at 5 years virtually of zero. Moreover, most of the long term
      survivors suffer from long-term side effects of the aggressive treatment. Thus, new
      therapeutic strategies are required that allow not only for more effective treatments of
      these tumors but also that defer the severe side effects derived from the current therapeutic
      choices. DNX-2401 is an oncolytic virus engineered to replicate specifically in tumor cells
      with an abnormal retinoblastoma (RB) pathway. Moreover, this virus infects cells through
      integrins, which are more abundant in glioma cells. Here we propose a phase I, unicentric,
      non-randomized clinical trial to study the safety and potential efficacy of intratumoral
      administration of DNX-2401 in DIPG. The virus administration will be done after stereotactic
      tumor biopsy, using the same trajectory, after verification of catheter position with
      intraoperative MRI. After 3-4 weeks patients will receive standard radiotherapy and/or
      chemotherapy. The primary objective is to confirm the safety of the target dose known from
      adults trials. Secondary endpoints are overall survival at 12 months (OS12), percentage of
      responses and induced immune response against tumor. The follow up includes close monitoring
      of neurological status, blood tests and brain MRI. If this trial shows evidence of safety and
      efficacy will propel a multicenter clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, tolerability and toxicity of DNX-2401 injected in the cerebellar peduncle</measure>
    <time_frame>12 weeks after virus injection</time_frame>
    <description>The trial will look for hematologic and neurologic toxicity (NCI-CTCAE v 4.03).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS12</measure>
    <time_frame>12 months after virus injection</time_frame>
    <description>Overall Survival at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Images response</measure>
    <time_frame>12 months after virus injection</time_frame>
    <description>Complete/partial response in MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>12 months after virus injection</time_frame>
    <description>measure quality of life baseline assessment and any changes over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Samples collection</measure>
    <time_frame>12 weeks after virus injection</time_frame>
    <description>Collect tumor and blood samples for futures molecular and immune studies.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Brainstem Glioma</condition>
  <condition>Neoadjuvant Therapy</condition>
  <arm_group>
    <arm_group_label>single arm treatment DNX-2401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm receiving virus DNX-2401 infusion after tumor biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNX-2401</intervention_name>
    <description>Brain infusion of the virus through the cerebellar peduncle</description>
    <arm_group_label>single arm treatment DNX-2401</arm_group_label>
    <other_name>Delta-24</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent OF PATIENT OR PARENTS

          2. Patient must be, in the investigator opinion, able to comply with all the protocol
             procedures.

          3. Age 1 - 18 years

          4. Negative pregnant blood test in case of fertile women (A woman is considered of
             childbearing potential (WOCBP), i.e. fertile, following menarche and unless
             permanently sterile. Permanent sterilization methods include hysterectomy, bilateral
             salpingectomy and bilateral oophorectomy.

          5. Patient newly diagnosed of DIPG in MRI

          6. Lansky Performance Status ≥ 70 before inclusion

          7. Lesion considered by the investigator to be accessible for stereotactic biopsy. Lesion
             location will allow injection without entrance of virus in the ventricular system.

          8. No previous treatment for DIPG

        Exclusion Criteria:

          1. Severe infections or intercurrent medical conditions including, but not limited to,
             severe renal, hepatic, heart or bone marrow failure, that, on investigator´s criteria,
             do not allow the inclusion. Patients must be afebrile at baseline [i.e., &lt; 38 degrees
             (Cº)].

          2. Investigational medication in the previous 30 days.

          3. Subjects with immunodeficiency, autoimmune conditions or active hepatitis.

          4. Any medical or psychological condition that might interfere with the subject's ability
             to participate if older than 16 years or parents ability when younger than 16, or give
             informed consent or would compromise the patient's ability to tolerate therapy or any
             disease that will obscure toxicity or dangerously alter drug metabolism.

          5. Tumor with multiple locations or doubt in MRI of a DIPG.

          6. Pregnant or breast-feeding females will be excluded, due to the risk for the fetal
             development of a recombinant virus containing genes related to cellular growth and
             differentiation.

          7. Severe bone marrow hypoplasia.

          8. AST (aspartate transaminase) and/or ALT (alanine transaminase)&gt; 3 times over upper
             normal laboratory level

          9. Neutrophils &lt; 1 x 109/L

         10. Thrombocytes ≤ 100 x 109/L

         11. Hemoglobin &lt; 9g/dl

        13. Patients with Li-Fraumeni Syndrome or with a known germ line deficit in the
        retinoblastoma gene or its related pathways.

        14. Vaccinations of any kind within 30 days prior to DNX-2401 administration. 15.
        Transfusions or medications (G-CSF) to treat pancytopenia or other hematological conditions
        within 28 days of baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonia Tejada, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sonia Tejada, MD, PhD</last_name>
    <phone>0034948255400</phone>
    <phone_ext>4590</phone_ext>
    <email>stejada@unav.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jose M Galindo</last_name>
    <phone>0034948255400</phone>
    <phone_ext>2527</phone_ext>
    <email>jgalindom@unav.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31190</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Tejada, MD, PhD</last_name>
      <phone>948255400</phone>
      <phone_ext>4590</phone_ext>
      <email>stejada@unav.es</email>
    </contact>
    <contact_backup>
      <last_name>Jose Maria Galindo</last_name>
      <phone>948255400</phone>
      <phone_ext>2527</phone_ext>
      <email>jgalindom@unav.es</email>
    </contact_backup>
    <investigator>
      <last_name>Ricardo Diez Valle, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Alonso, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Patiño, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maite Garriz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miriam Giraldez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Tejada, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007 Dec 15;67(24):11499-504.</citation>
    <PMID>18089777</PMID>
  </results_reference>
  <results_reference>
    <citation>Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E, Heymans MW, Warmuth-Metz M, Hargrave D, van der Hoeven EJ, Gidding CE, de Bont ES, Eshghi OS, Reddingius R, Peeters CM, Schouten-van Meeteren AY, Gooskens RH, Granzen B, Paardekooper GM, Janssens GO, Noske DP, Barkhof F, Kramm CM, Vandertop WP, Kaspers GJ, van Vuurden DG. Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol. 2015 Jan;17(1):160-6. doi: 10.1093/neuonc/nou104. Epub 2014 Jun 5.</citation>
    <PMID>24903904</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF, Fueyo J. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007 Sep 19;99(18):1410-4. Epub 2007 Sep 11.</citation>
    <PMID>17848677</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2017</study_first_submitted>
  <study_first_submitted_qc>June 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>June 3, 2017</last_update_submitted>
  <last_update_submitted_qc>June 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinica Universidad de Navarra, Universidad de Navarra</investigator_affiliation>
    <investigator_full_name>Sonia Tejada</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Diffuse intrinsic pontine gliomas</keyword>
  <keyword>Oncolytic adenovirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>During the trail the results will be presented in scientific meetings. After the trial, a paper will be published by the IP</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

